Cleveland Diagnostics
Cleveland Diagnostics Aims to Drive IsoPSA Test Into New Prostate Cancer Indications, Markets
Premium
Backed by $75 million in new funding, the firm looks to establish additional use cases for the test and, via its deal with Quest Diagnostics, target primary care.
Cleveland Diagnostics Closes $75M Private Financing
The company will use the funds for development and commercialization of its portfolio of cancer early detection tests, including its IsoPSA test for prostate cancer.
In Brief This Week: Quest Diagnostics, Ginkgo Bioworks, Novacyt, Danaher, and More
News items for the in vitro diagnostics industry for the week of May 3, 2021.
Cleveland Diagnostics Raises $19.4M
The company said the funding would be used to further commercialize its IsoPSA blood-based prostate-specific antigen assay and to develop tests for other cancers.